aod9604 fat loss efficacy mechanism side effects AOD 9604: The Ultimate Guide to Loss, Tissue Repair, and Metabolic Health The difference between AOD 9604

Results demonstrated that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo. Critically, the peptide produced no clinically significant alterations in IGF-1 levels, no glucose intolerance or insulin resistance, and no anti-AOD9604 antibodies in any participant

Researchers at Monash University recognized that many individuals seeking fat loss could not tolerate or did not need growth hormones broader effects including muscle growth, glucose elevation, and IGF-1 stimulation

The most commonly reported side effect was mild headache, occurring at rates comparable to placebo

Our team is here to help you